Implication of the polyamine system in mental disorders

Journal of Psychiatry and Neuroscience

Volumn 33, Issue 2, 2008, Pages 102-110

  Fiori, Laura M ^a   Turecki, Gustavo ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

Depression; Mental disorders; Polyamines; Schizophrenia; Stress; Suicide

Indexed keywords

AGMATINE; POLYAMINE; PUTRESCINE;

ANXIETY; CELL FUNCTION; ENZYME ACTIVITY; HUMAN; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SUICIDAL BEHAVIOR;

EID: 41149114638     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Li G, Regunathan S, Barrow CJ, et al. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 1994;263:966-9.
2. Moinard C, Cynober L, de Bandt JP. Polyamines: metabolism and implications in human diseases. Clin Nutr 2005;24:184-97.
3. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984;53:749-90.
4. Ikeguchi Y, Bewley MC, Pegg AE. Aminopropyltransferases: function, structure and genetics. J Biochem 2006;139:1-9.
5. Wang Y, Casero RA Jr. Mammalian polyamine catabolism: a therapeutic target, a pathological problem, or both? J Biochem 2006;139:17-25.
6. Cabella C, Gardini G, Corpillo D, et al. Transport and metabolism of agmatine in rat hepatocyte cultures. Eur J Biochem 2001;268:940-7.
7. Masuko T, Kusama-Eguchi K, Sakata K, et al. Polyamine transport, accumulation, and release in brain. J Neurochem 2003;84:610-7.
8. Goracke-Postle CJ, Overland AC, Stone LS, et al. Agmatine transport into spinal nerve terminals is modulated by polyamine analogs. J Neurochem 2007;100:132-41.
9. Bernstein HG, Muller M. The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Prog Neurobiol 1999;57:485-505.
10. Piletz JE, May PJ, Wang G, et al. Agmatine crosses the blood-brain barrier. Ann N Y Acad Sci 2003;1009:64-74.
11. Shin WW, Fong WF, Pang SF, et al. Limited blood-brain barrier transport of polyamines. J Neurochem 1985;44:1056-9.
12. Seiler N. Polyamine metabolism and function in brain. Neurochem Int 1981;3:95-110.
13. Morrison LD, Becker L, Kish SJ. S-adenosylmethionine decarboxylase in human brain. Regional distribution and influence of aging. Brain Res Dev Brain Res 1993;73:237-41.
14. Morrison LD, Becker L, Ang LC, et al. Polyamines in human brain: regional distribution and influence of aging. J Neurochem 1995;65:636-42.
15. Zoli M, Pedrazzi P, Agnati LF. Regional and cellular distribution of spermidine/spermine N1-acetyltransferase (SSAT) mRNA in the rat central nervous system. Neurosci Lett 1996;207:13-6.
16. Morrison LD, Cao XC, Kish SJ. Ornithine decarboxylase in human brain: influence of aging, regional distribution, and Alzheimer's disease. J Neurochem 1998;71:288-94.
17. Laube G, Veh RW. Astrocytes, not neurons, show most prominent staining for spermidine/spermine-like immunoreactivity in adult rat brain. Glia 1997;19:171-9.
18. Laube G, Bernstein HG, Wolf G, et al. Differential distribution of spermidine/spermine-like immunoreactivity in neurons of the adult rat brain. J Comp Neurol 2002;444:369-86.
19. Krauss M, Langnaese K, Richter K, et al. Spermidine synthase is prominently expressed in the striatal patch compartment and in putative interneurones of the matrix compartment. J Neurochem 2006;97:174-89.
20. Iyo AH, Zhu MY, Ordway GA, et al. Expression of arginine decarboxylase in brain regions and neuronal cells. J Neurochem 2006;96:1042-50.
21. Schuber F. Influence of polyamines on membrane functions. Biochem J 1989;260:1-10.
22. Drolet G. Radical scavenging properties of polyamines. Phytochemistry 1986;25:367-71.
23. Lovaas E, Carlin G. Spermine: an anti-oxidant and anti-inflammatory agent. Free Radic Biol Med 1991;11:455-61.
24. Seiler N, Raul F. Polyamines and apoptosis. J Cell Mol Med 2005; 9:623-42.
25. Gilad GM, Gilad VH. Overview of the brain polyamine-stress-response: regulation, development, and modulation by lithium and role in cell survival. Cell Mol Neurobiol 2003;23:637-49.
26. Williams K. Modulation and block of ion channels: a new biology of polyamines. Cell Signal 1997;9:1-13.
27. Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 2000;21:187-93.
28. Bastida CM, Cremades A, Castells MT, et al. Sexual dimorphism of ornithine decarboxylase in the mouse adrenal: influence of polyamine deprivation on catecholamine and corticoid levels. Am J Physiol Endocrinol Metab 2007;292:E1010-7.
29. Bo P, Giorgetti A, Camana C, et al. EEG and behavioural effects of polyamines (spermine and spermidine) on rabbits. Pharmacol Res 1990;22:481-91.
30. Hirsch SR, Richardson-Andrews R, Costall B, et al. The effects of some polyamines on putative behavioural indices of mesolimbic versus striatal dopaminergic function. Psychopharmacology (Berl) 1987;93:101-4.
31. Ritz MC, Mantione CR, London ED. Spermine interacts with cocaine binding sites on dopamine transporters. Psychopharmacology (Berl) 1994;114:47-52.
32. Deckardt K, Pujol JF, Belin MF, et al. Increase of ornithine decarboxylase activity elicited by reserpine in the peripheral and central monoaminergic systems of the rat. Neurochem Res 1978;3:745-53.
33. Brackley P, Goodnow R Jr, Nakanishi K, et al. Spermine and philanthotoxin potentiate excitatory amino acid responses of Xenopus oocytes injected with rat and chick brain RNA. Neurosci Lett 1990;114:51-6.
34. Gilad GM, Gilad VH, Wyatt RJ. Polyamines modulate the binding of GABAA-benzodiazepine receptor ligands in membranes from the rat forebrain. Neuropharmacology 1992;31:895-8.
35. Morgan PF, Stone TW. Structure-activity studies on the potentiation of benzodiazepine receptor binding by ethylenediamine analogues and derivatives. Br J Pharmacol 1983;79:973-7.
36. Seiler N. Catabolism of polyamines. Amino Acids 2004;26:217-33.
37. Galea E, Regunathan S, Eliopoulos V, et al. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996;316:247-9.
38. Lynch DR, Gallagher MJ. Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors. J Pharmacol Exp Ther 1996;279:154-61.
39. Shim SS, Grant ER, Singh S, et al. Actions of butyrophenones and other antipsychotic agents at NMDA receptors: relationship with clinical effects and structural considerations. Neurochem Int 1999;34:167-75.
40. Zomkowski AD, Hammes L, Lin J, et al. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 2002;13:387-91.
41. Li YF, Gong ZH, Cao JB, et al. Antidepressant-like effect of agmatine and its possible mechanism. Eur J Pharmacol 2003;469:81-8.
42. Zomkowski AD, Santos AR, Rodrigues AL. Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1419-25.
43. Richardson-Andrews RC. A central role for the polyamines in the aetiology of schizophrenia. Med Hypotheses 1983;11:157-66.
44. Andrews RC. The side effects of antimalarial drugs indicates a polyamine involvement in both schizophrenia and depression. Med Hypotheses 1985;18:11-8.
45. Meltzer HY, Arora RC, Jackman H, et al. Platelet monoamine oxidase and plasma amine oxidase in psychiatric patients. Schizophr Bull 1980;6:213-9.
46. Baron M, Gruen R, Levitt M, et al. Neuroleptic drug effect on platelet monoamine oxidase and plasma amine oxidase in schizophrenia. Psychiatry Res 1982;7:179-87.
47. Baron M, Asnis L, Gruen R, et al. Plasma amine oxidase and genetic vulnerability to schizophrenia. Arch Gen Psychiatry 1983;40:275-9.
48. Baron M, Risch N, Levitt M, et al. Genetic analysis of plasma amine oxidase activity in schizophrenia. Psychiatry Res 1985;15:121-32.
49. Gruen R, Baron M, Levitt M, et al. Plasma amine oxidase and clinical features of schizophrenia. Am J Psychiatry 1985;142:972-3.
50. Svinarev VI. [Serum spermidine levels of schizophrenic patients.] [Article in Russian.] Zh Nevropatol Psikhiatr Im S S Korsakova 1987;87:732-4.
51. Flayeh KA. Spermidine Oxidase Activity in Serum of Normal and Schizophrenic Subjects. Clin Chem 1988;34:401-3.
52. Das I, de Belleroche J, Essali M, et al. Plasma polyamine oxidase in normal and schizophrenic subjects. Schizophr Res 1990;3:37-8.
53. Das I, Adams C, Essali MA, et al. Blood polyamines in schizophrenia: A study of clozapine in drug resistant schizophrenic patients. Schizophr Res 1992;6:175.
54. Ramchand CN, Das I, Gliddon A, et al. Role of polyamines in the membrane pathology of schizophrenia. A study using fibroblasts from schizophrenic patients and normal controls. Schizophr Res 1994;13:249-53.
55. Gilad GM, Gilad VH, Casanova MF, et al. Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders. Biol Psychiatry 1995;38:227-34.
56. Bernstein H-G, Henning H, Danos P, et al. A morphometric and immunohistochemical study of the rostral entorhinal cortex in neuropsychiatrie patients and controls: heterotopically displaced lamina II neurons are not indicative of schizophrenia. Society for Neuroscience 1997 Annual Meeting; 1997 Oct 25-30; New Orleans. Washington: Society for Neuroscience; 1997.
57. Das I, Ramchand CN, Gliddon A, et al. Nitric oxide, free radicals and polyamines may have a role in the membrane pathology of schizophrenia. Neuropsychobiology 1998;37:65-7.
58. Dahel KA, Al Saffar NM, Flayeh KA. Polyamine oxidase activity in sera of depressed and schizophrenic patients after ECT treatment. Neurochem Res 2001;26:415-8.
59. Middleton FA, Mimics K, Pierri JN, et al. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 2002;22:2718-29.
60. Das I, de Belleroche J, Essali MA, et al. Blood polyamine in schizophrenia. Schizophr Res 1989;2:146.
61. Bernstein HG, Grecksch G, Becker A, et al. Cellular changes in rat brain areas associated with neonatal hippocampal damage. Neuroreport 1999;10(11):2307-11.
62. Bondy SC, Mitchell CL, Rahmaan S, et al. Regional variation in the response of cerebral ornithine decarboxylase to electroconvulsive shock. Neurochem Pathol 1987;7:129-41.
63. Orzi F, Zoli M, Passarelli F, et al. Repeated electroconvulsive shock increases glial fibrillary acidic protein, ornithine decarboxylase, somatostatin and cholecystokinin immunoreactivities in the hippocampal formation of the rat. Brain Res 1990;533:223-31.
64. Olney JW. Excitatory amino acids and neuropsychiatrie disorders. Biol Psychiatry 1989;26:505-25.
65. Halaris A, Zhu H, Feng Y, et al. Plasma agmatine and platelet imidazoline receptors in depression. Ann N Y Acad Sci 1999;881:445-51.
66. Sequeira A, Gwadry FG, Ffrench-Mullen JM, et al. Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry 2006;63:35-48.
67. Sequeira A, Klempan T, Canetti L, et al. Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry 2007;12:640-55.
68. Genedani S, Saltini S, Benelli A, et al. Influence of SAMe on the modifications of brain polyamine levels in an animal model of depression. Neuroreport 2001;12:3939-42.
69. Aricioglu F, Altunbas H. Is agmatine an endogenous anxiolytic/ antidepressant agent? Ann NY Acad Sci 2003;1009:136-40.
70. Zomkowski AD, Rosa AO, Lin J, et al. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res 2004;1023:253-63.
71. Zomkowski AD, Santos AR, Rodrigues AL. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 2005;381:279-83.
72. Zeidan MP, Zomkowski AD, Rosa AO, et al. Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur J Pharmacol 2007;565:125-31.
73. Butler SR, Schanberg SM. Effect of maternal deprivation on polyamine metabolism in preweanling rat brain and heart. Life Sci 1977;21:877-84.
74. Gilad GM, Gilad VH, Wyatt RJ, et al. Chronic lithium treatment prevents the dexamethasone-induced increase of brain polyamine metabolizing enzymes. Life Sci 1992;50:PL149-54.
75. Gilad GM, Gilad VH. Brain polyamine stress response: recurrence after repetitive stressor and inhibition by lithium. J Neurochem 1996;67:1992-6.
76. Gilad GM, Gilad VH, Eliyayev Y, et al. Developmental regulation of the brain polyamine-stress-response. Int J Dev Neurosci 1998; 16:271-8.
77. Gilad VH, Rabey JM, Eliyayev Y, et al. Different effects of acute neonatal stressors and long-term postnatal handling on stress-induced changes in behavior and in ornithine decarboxylase activity of adult rats. Brain Res Dev Brain Res 2000;120:255-9.
78. Gilad VH, Rabey JM, Kimiagar Y, et al. The polyamine stress response: tissue-, endocrine-, and developmental-dependent regulation. Biochem Pharmacol 2001;61:207-13.
79. Gilad GM, Gilad VH. Stress-induced dynamic changes in mouse brain polyamines. Role in behavioral reactivity. Brain Res 2002;943:23-9.
80. Sohn HS, Park YN, Lee SR. Effect of immobilization stress on brain polyamine levels in spontaneously hypertensive and Wistar-Kyoto rats. Brain Res Bull 2002;57:575-9.
81. Lavinsky D, Arteni NS, Netto CA. Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behav Brain Res 2003; 141:19-24.
82. Aricioglu F, Regunathan S, Piletz JE. Is agmatine an endogenous factor against stress? Ann N Y Acad Sci 2003;1009:127-32.
83. Hayashi Y, Tanaka J, Morizumi Y, et al. Polyamine levels in brain and plasma after acute restraint or water-immersion restraint stress in mice. Neurosci Lett 2004;355:57-60.
84. Gong ZH, Li YF, Zhao N, et al. Anxiolytic effect of agmatine in rats and mice. Eur J Pharmacol 2006;550:112-6.
85. Li YF, Chen HX, Liu Y, et al. Agmatine increases proliferation of cultured hippocampal progenitor cells and hippocampal neurogenesis in chronically stressed mice. Acta Pharmacol Sin 2006;27:1395-400.
86. Lee SH, Jung BH, Kim SY, et al. The antistress effect of ginseng total saponin and ginsenoside Rg3 and Rb1 evaluated by brain polyamine level under immobilization stress. Pharmacol Res 2006;54:46-9.
87. Zawia NH, Bondy SC. Electrically stimulated rapid gene expression in the brain: ornithine decarboxylase and c-fos. Brain Res Mol Brain Res 1990;7:243-7.
88. Layer RT, Popik P, Olds T, et al. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol Biochem Behav 1995;52:621-7.
89. Williams AL, Girard C, Jui D, et al. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med 2005;28:132-9.
90. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002;76:1158S-61S.
91. Gilad GM, Gilad VH. Polyamine biosynthesis is required for survival of sympathetic neurons after axonal injury. Brain Res 1983;273:191-4.
92. Halonen T, Sivenius J, Miettinen R, et al. Elevated seizure threshold and impaired spatial learning in transgenic mice with putrescine overproduction in the brain. Eur J Neurosci 1993;5:1233-9.
93. Kaasinen SK, Oksman M, Alhonen L, et al. Spermidine/spermine Nl-acetyltransferase overexpression in mice induces hypoactivity and spatial learning impairment. Pharmacol Biochem Behav 2004;78:35-45.
94. Janne J, Alhonen L, Pietila M, et al. Genetic approaches to the cellular functions of polyamines in mammals. Eur J Biochem 2004;271:877-94.
95. Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J Psychiatry Neurosci 2004;29:185-93.
96. Richards JF, Fox K, Peng T, et al. Inhibition of hormone-stimulated ornithine decarboxylase activity by lithium chloride. Life Sci 1990;47:233-40.
97. Gilad GM, Gilad VH. Astroglia growth retardation and increased microglia proliferation by lithium and ornithine decarboxylase inhibitor in rat cerebellar cultures: Cytotoxicity by combined lithium and polyamine inhibition. J Neurosci Res 2007;85:594-601.